MIROMATRIX MEDICAL INC (MIRO) Fundamental Analysis & Valuation

NASDAQ:MIROUS60471P1084

Current stock price

3.39 USD
+0.02 (+0.59%)
At close:
3.39 USD
0 (0%)
After Hours:

This MIRO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MIRO Profitability Analysis

1.1 Basic Checks

  • In the past year MIRO has reported negative net income.
  • MIRO had a negative operating cash flow in the past year.
MIRO Yearly Net Income VS EBIT VS OCF VS FCFMIRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of MIRO (-117.04%) is worse than 95.08% of its industry peers.
  • Looking at the Return On Equity, with a value of -176.38%, MIRO is doing worse than 88.52% of the companies in the same industry.
Industry RankSector Rank
ROA -117.04%
ROE -176.38%
ROIC N/A
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MIRO Yearly ROA, ROE, ROICMIRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

  • Looking at the Gross Margin, with a value of 47.92%, MIRO is in line with its industry, outperforming 54.10% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for MIRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRO Yearly Profit, Operating, Gross MarginsMIRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -10K -20K -30K -40K -50K

4

2. MIRO Health Analysis

2.1 Basic Checks

  • MIRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MIRO has more shares outstanding
  • Compared to 1 year ago, MIRO has an improved debt to assets ratio.
MIRO Yearly Shares OutstandingMIRO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 5M 10M 15M 20M
MIRO Yearly Total Debt VS Total AssetsMIRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -3.73, we must say that MIRO is in the distress zone and has some risk of bankruptcy.
  • MIRO has a Altman-Z score of -3.73. This is amonst the worse of the industry: MIRO underperforms 88.52% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that MIRO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.03, MIRO is in line with its industry, outperforming 59.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -3.73
ROIC/WACCN/A
WACC12.72%
MIRO Yearly LT Debt VS Equity VS FCFMIRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • MIRO has a Current Ratio of 3.46. This indicates that MIRO is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.46, MIRO perfoms like the industry average, outperforming 57.38% of the companies in the same industry.
  • A Quick Ratio of 3.46 indicates that MIRO has no problem at all paying its short term obligations.
  • MIRO's Quick ratio of 3.46 is fine compared to the rest of the industry. MIRO outperforms 62.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46
MIRO Yearly Current Assets VS Current LiabilitesMIRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 10M 20M 30M 40M 50M

7

3. MIRO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.99% over the past year.
  • The Revenue has grown by 3100.00% in the past year. This is a very strong growth!
  • MIRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 56.05% yearly.
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.77% on average over the next years. This is quite good.
  • MIRO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 490.87% yearly.
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MIRO Yearly Revenue VS EstimatesMIRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
MIRO Yearly EPS VS EstimatesMIRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8 10

0

4. MIRO Valuation Analysis

4.1 Price/Earnings Ratio

  • MIRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MIRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRO Price Earnings VS Forward Price EarningsMIRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRO Per share dataMIRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.41%
EPS Next 3Y7.54%

0

5. MIRO Dividend Analysis

5.1 Amount

  • No dividends for MIRO!.
Industry RankSector Rank
Dividend Yield N/A

MIRO Fundamentals: All Metrics, Ratios and Statistics

MIROMATRIX MEDICAL INC

NASDAQ:MIRO (12/12/2023, 8:00:01 PM)

After market: 3.39 0 (0%)

3.39

+0.02 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners22.32%
Inst Owner Change-7.87%
Ins Owners108.14%
Ins Owner Change0%
Market Cap92.95M
Revenue(TTM)960.00K
Net Income(TTM)-27.41M
Analysts80
Price Target3.19 (-5.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.41%
Min EPS beat(2)-12.04%
Max EPS beat(2)18.86%
EPS beat(4)2
Avg EPS beat(4)3.41%
Min EPS beat(4)-12.04%
Max EPS beat(4)18.86%
EPS beat(8)3
Avg EPS beat(8)-11.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)180.11%
Min Revenue beat(2)180.11%
Max Revenue beat(2)180.11%
Revenue beat(4)4
Avg Revenue beat(4)6622.69%
Min Revenue beat(4)180.11%
Max Revenue beat(4)25950.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)99900%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.83
P/FCF N/A
P/OCF N/A
P/B 5.98
P/tB 5.98
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.04
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -117.04%
ROE -176.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.92%
FCFM N/A
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.83%
Cap/Sales 23.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -3.73
F-Score3
WACC12.72%
ROIC/WACCN/A
Cap/Depr(3y)718.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)3872.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
EBIT growth 1Y0.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.34%
EBIT Next 3Y-21.4%
EBIT Next 5YN/A
FCF growth 1Y-135.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.27%
OCF growth 3YN/A
OCF growth 5YN/A

MIROMATRIX MEDICAL INC / MIRO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MIROMATRIX MEDICAL INC (MIRO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MIRO.


What is the valuation status of MIROMATRIX MEDICAL INC (MIRO) stock?

ChartMill assigns a valuation rating of 0 / 10 to MIROMATRIX MEDICAL INC (MIRO). This can be considered as Overvalued.


Can you provide the profitability details for MIROMATRIX MEDICAL INC?

MIROMATRIX MEDICAL INC (MIRO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MIRO stock?

The Earnings per Share (EPS) of MIROMATRIX MEDICAL INC (MIRO) is expected to grow by 32.47% in the next year.